Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective

PharmacoEconomics

Volumn 25, Issue 4, 2007, Pages 329-342

  Delea, Thomas E ^a   Sofrygin, Oleg ^a   Thomas, Simu K ^b   Baladi, Jean Francois ^b   Phatak, Pradyumna D ^c   Coates, Thomas D ^d  

^a POLICY ANALYSIS INC PAI   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ROCHESTER GENERAL HOSPITAL   (United States)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DEFERASIROX; DEFEROXAMINE; DEFEROXAMINE MESYLATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ARTICLE; BLOOD TRANSFUSION; CHELATION THERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART DISEASE; HUMAN; IRON OVERLOAD; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RASH; THALASSEMIA MAJOR;

ADMINISTRATION, ORAL; BENZOIC ACIDS; BETA-THALASSEMIA; BLOOD TRANSFUSION; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION REVIEW; ECONOMICS, PHARMACEUTICAL; HUMANS; INFUSIONS, INTRAVENOUS; INSURANCE CLAIM REVIEW; IRON CHELATING AGENTS; IRON OVERLOAD; MARKOV CHAINS; TREATMENT OUTCOME; TRIAZOLES; UNITED STATES;

EID: 34247271478     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725040-00005     Document Type: Article

References (40)

1. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996; 95: 26-36
2. Cohen A. Management of iron overload in the pediatric patient. Hematol Oncol Clin North Am 1987; 3: 521-44
3. Arboretti R, Tognoni G, Alberti D. Pharmacosurveillance and quality of care of thalassaemic patients. Eur J Clin Pharmacol 2001; 56: 915-22
4. Nick H-P, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 2003; 10: 1065-76
5. Cappellini MD, Cohen A, Piga A, et al. A phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with. Blood 2006; 107 (9): 3455-62
6. Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001; 4 (5): 348-61
7. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13 (4): 322-38
8. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices. Modeling studies. Value Health 2003; 6 (1): 9-17
9. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89 (10): 1187-93
10. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989; 2 (8653): 27-30
11. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006 May 1; 107 (Epub 2005 Dec 13): 3738-44
12. Fischer R, Longo F, Nielsen P, et al. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferri-oxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003; 121 (6): 938-48
13. Piga A, Gagliotti C, Fogliacco E, et al. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88: 489-96
14. Boturao-Neto E, Marcopito LF, Zago MA. Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients. Braz J Med Biol Res 2002; 35 (11): 1319-28
15. Maggio A, D'Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002; 28: 196-208
16. Ward A, Caro JJ, Green TC, et al. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol 2002; 2: 3
17. Taher A, Sheikh-Taha M, Koussa S, et al. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Eur J Haematol 2001; 67 (1): 30-4
18. Richardson ME, Matthews RN, Alison JF, et al. Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major. Aust N Z J Med 1993; 23: 656-61
19. Beratis S. Noncompliance with iron chelation therapy in patients with beta thalassaemia. J Psychosom Res 1989; 33: 739-45
20. Wolfe L, Olivieri N, Sallan D, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985; 312 (25): 1600-3
21. Murri R, Antinori A, Ammassari A, et al. AdICoNA Study Group. Physician estimates of adherence and the patient-physician relationship as a setting to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2002 Dec 15; 31 Suppl. 3: S158-62.
22. Kalbfleisch JD, Prentic RL. The statistical analysis of failure time data. New York: John Wiley & Sons, Inc., 1980
23. Kremastinos DT, Tsetsos GA, Tsiapras DP, et al. Heart failure in beta thalassemia: a 5-year follow-up study. Am J Med 2001; 111 (5): 349-54
24. Anderson RN. United States life tables, 1998. National Vital Statistics Reports 2001; 48 (18) [online]. Available from URL: http://www.cdc.gov [Accessed 2006 Jun 21]
25. Bureau of Labor Statistics. Consumer price index. Washington, DC: US Department of Labor, 2006 [online]. Available from URL: http://data.bls.gov/cgi- bin/surveymost [Accessed 2006 Mar 5]
26. Red Book Update December 2006. Montvale (NJ): Thomson Healthcare Inc., 2005
27. Delea TE, Sofrygin O, Baladi J-F, et al. Costs and consequences of inadequate compliance with deferoxamine therapy in patients with transfusion-dependent thalassemia: session type [abstract 3134]. Blood 2005; 106 (11 Pt 1): 877a
28. De Abreu Lourenco R, Osborne R, Dalton A, et al. An oral iron chelator and quality of life [abstract 5553]. Blood 2005, 106 (11 Part 2)
29. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13 (2): 89-102
30. Briggs AH. A bayesian approach to stochastic cost-effectiveness analysis. Health Econ 1999; 8: 257-61
31. Weinstein MC, Fineberg HV, Elstein AS, et al. Clinical decision analysis. Philadelphia: W.B. Saunders, 1980: 260
32. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20 (3): 332-42
33. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation. Arch Intern Med 2003; 163: 1637-41
34. Pearson HA, Cohen AR, Giardina PJ, et al. The changing profile of homozygous beta-thalassemia: demography, ethnicity, and age distribution of current North American patients and changes in two decades. Pediatrics 1996; 97 (3): 352-6
35. SM deferasirox (exjade® ) [Novartis]. March 2006 [online]. Available from URL: http://www.regencerx.com/learn/physicianRx/index.html [Accessed 2006 Nov 12]
36. DeSwarte-Wallace J, Groncy PK, Finkelstein JZ. Iron chelation with deferoxamine: comparing the results of a critical pathway to a national survey. J Pediatr Hematol Oncol 1999; 21 (2): 136-41
37. Payne KA, Desrosiers MP, Proskorovsky I, et al. Total annual costs of infused iron chelation therapy in the United states [abstract 3360]. Poster presented at the American Society of Hematology 2006 Annual Meeting; 2006 Dec 11; Orlando
38. Cunningham MJ, Macklin EA, Neufeld EJ, et al. Thalassemia Clinical Research Network: complications of beta-thalassemia major in North America. Blood 2004; 104 (1): 34-9
39. Johnson ES, Sullivan SD, Mozaffari E, et al. A utility assessment of oral and intravenous ganciclovir for the maintenance treatment of AIDS-related cytomegalovirus retinitis. Pharmacoeconomics 1996; 10 (6): 623-9
40. Cappellini MD, Bejaoui M, Agaoglu L, et al. Patient satisfaction with deferasirox (exjade. Blood 2005; 106 (11 Pt 1): 759a